Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacteriophages | 5 | 2024 | 53 | 2.600 |
Why?
|
| Phage Therapy | 3 | 2024 | 6 | 1.940 |
Why?
|
| Microbiota | 3 | 2023 | 411 | 1.460 |
Why?
|
| Probiotics | 4 | 2023 | 88 | 1.440 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2024 | 533 | 1.350 |
Why?
|
| Genetic Engineering | 4 | 2025 | 118 | 1.210 |
Why?
|
| Bacteria | 7 | 2025 | 497 | 1.200 |
Why?
|
| Carbapenems | 2 | 2024 | 12 | 0.970 |
Why?
|
| Klebsiella Infections | 1 | 2024 | 30 | 0.920 |
Why?
|
| Biosensing Techniques | 3 | 2023 | 76 | 0.920 |
Why?
|
| Klebsiella pneumoniae | 1 | 2024 | 39 | 0.920 |
Why?
|
| Gastrointestinal Tract | 3 | 2024 | 191 | 0.760 |
Why?
|
| Colitis | 2 | 2022 | 251 | 0.760 |
Why?
|
| Bacterial Infections | 1 | 2022 | 185 | 0.720 |
Why?
|
| Anti-Bacterial Agents | 2 | 2024 | 803 | 0.650 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2021 | 452 | 0.590 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 605 | 0.540 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 265 | 0.540 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 151 | 0.540 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 2347 | 0.440 |
Why?
|
| Virulence Factors | 3 | 2024 | 114 | 0.390 |
Why?
|
| Animals | 13 | 2025 | 27783 | 0.370 |
Why?
|
| Neoplasms | 1 | 2025 | 3053 | 0.330 |
Why?
|
| Mice | 8 | 2024 | 11993 | 0.320 |
Why?
|
| Virulence | 2 | 2024 | 282 | 0.300 |
Why?
|
| Host Specificity | 2 | 2024 | 13 | 0.280 |
Why?
|
| Prebiotics | 2 | 2024 | 8 | 0.260 |
Why?
|
| Bacteroidetes | 2 | 2024 | 39 | 0.250 |
Why?
|
| Feces | 2 | 2024 | 339 | 0.250 |
Why?
|
| CRISPR-Cas Systems | 2 | 2024 | 85 | 0.240 |
Why?
|
| Plasmids | 2 | 2024 | 292 | 0.240 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2024 | 10 | 0.240 |
Why?
|
| Synbiotics | 1 | 2024 | 2 | 0.230 |
Why?
|
| Hypersensitivity | 2 | 2023 | 163 | 0.230 |
Why?
|
| Containment of Biohazards | 1 | 2024 | 9 | 0.230 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 52 | 0.230 |
Why?
|
| Lactulose | 1 | 2024 | 22 | 0.230 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2023 | 10 | 0.220 |
Why?
|
| Drug Delivery Systems | 1 | 2025 | 181 | 0.220 |
Why?
|
| Metagenome | 1 | 2024 | 109 | 0.210 |
Why?
|
| Food Hypersensitivity | 1 | 2024 | 72 | 0.210 |
Why?
|
| Hydrogen Sulfide | 1 | 2023 | 52 | 0.210 |
Why?
|
| beta-N-Acetylhexosaminidases | 1 | 2022 | 4 | 0.210 |
Why?
|
| Nitric Oxide | 1 | 2023 | 281 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2022 | 152 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 483 | 0.180 |
Why?
|
| Bone and Bones | 1 | 2022 | 273 | 0.180 |
Why?
|
| Humans | 12 | 2025 | 91074 | 0.170 |
Why?
|
| Bacteriophage T3 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Viral Tail Proteins | 1 | 2019 | 3 | 0.170 |
Why?
|
| Inflammation | 2 | 2023 | 998 | 0.170 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 8 | 0.170 |
Why?
|
| Escherichia coli Infections | 1 | 2019 | 34 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 453 | 0.160 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2018 | 2 | 0.150 |
Why?
|
| Heme | 1 | 2018 | 64 | 0.150 |
Why?
|
| Anti-Infective Agents | 2 | 2016 | 91 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2022 | 809 | 0.140 |
Why?
|
| Swine | 1 | 2018 | 594 | 0.130 |
Why?
|
| Biomarkers | 1 | 2023 | 1814 | 0.130 |
Why?
|
| Escherichia coli | 1 | 2019 | 612 | 0.130 |
Why?
|
| Bioengineering | 1 | 2016 | 14 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 241 | 0.120 |
Why?
|
| Enterohemorrhagic Escherichia coli | 1 | 2014 | 1 | 0.120 |
Why?
|
| Drug Resistance, Microbial | 1 | 2014 | 75 | 0.120 |
Why?
|
| Synthetic Biology | 1 | 2014 | 15 | 0.120 |
Why?
|
| Gene Targeting | 1 | 2014 | 74 | 0.120 |
Why?
|
| Ribonucleases | 1 | 2014 | 93 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2014 | 65 | 0.110 |
Why?
|
| Citrobacter rodentium | 1 | 2012 | 14 | 0.100 |
Why?
|
| Vesicular Transport Proteins | 1 | 2012 | 66 | 0.100 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2009 | 5 | 0.080 |
Why?
|
| Tight Junctions | 1 | 2009 | 151 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2009 | 184 | 0.070 |
Why?
|
| Intestines | 1 | 2009 | 419 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 2416 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 906 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 3303 | 0.060 |
Why?
|
| Female | 3 | 2024 | 47186 | 0.060 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2024 | 78 | 0.060 |
Why?
|
| Thymidine | 1 | 2024 | 59 | 0.060 |
Why?
|
| Germ-Free Life | 1 | 2024 | 78 | 0.060 |
Why?
|
| Butyrates | 1 | 2024 | 50 | 0.060 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2023 | 19 | 0.060 |
Why?
|
| Remote Sensing Technology | 1 | 2023 | 8 | 0.050 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2023 | 20 | 0.050 |
Why?
|
| Capsules | 1 | 2023 | 38 | 0.050 |
Why?
|
| Luminescence | 1 | 2023 | 20 | 0.050 |
Why?
|
| Wireless Technology | 1 | 2023 | 21 | 0.050 |
Why?
|
| Body Size | 1 | 2023 | 95 | 0.050 |
Why?
|
| CD8 Antigens | 1 | 2022 | 82 | 0.050 |
Why?
|
| Allergens | 1 | 2023 | 188 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 453 | 0.050 |
Why?
|
| Models, Animal | 1 | 2023 | 278 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2023 | 673 | 0.050 |
Why?
|
| Immune System Phenomena | 1 | 2019 | 1 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2012 | 516 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 76 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2019 | 284 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1493 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 3204 | 0.040 |
Why?
|
| Time Factors | 1 | 2023 | 5378 | 0.030 |
Why?
|
| Research | 1 | 2014 | 252 | 0.030 |
Why?
|
| PDZ Domains | 1 | 2012 | 15 | 0.020 |
Why?
|
| COP-Coated Vesicles | 1 | 2012 | 22 | 0.020 |
Why?
|
| Secretory Pathway | 1 | 2012 | 22 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2012 | 101 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 371 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 210 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 335 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 2329 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 429 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 237 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2009 | 10 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2009 | 56 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2009 | 98 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2009 | 123 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2009 | 117 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 439 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2009 | 258 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 388 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 679 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 2615 | 0.010 |
Why?
|
| Male | 1 | 2024 | 43249 | 0.010 |
Why?
|